Each film-coated tablet contains Losartan potassium, 50mg and Amlodipine (as besilate), 5mg.
The usual initial dosage is one tablet daily. If blood pressure control is inadequate after a week or two, the dose may be increased to two tablets daily. The dosage, however, should be individualized.
The most likely manifestation of over dosage should be hypotension and tachycardia; bradycardia could occur from parasympathetic stimulation. If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to the conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention circulation volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. The combination cannot be removed by dialysis.
Treatment of mild to moderate hypertension. Treatment of patients with hypertension not responding to mono therapy with calcium antagonist or angiotensin II receptor antagonists.
The combination is contraindicated in the patients who are hypersensitive to any component of this product.
Congestive Heart failure: In general, calcium channel blockers should be used with caution in patients with heart failure. Electrolyte Imbalance: Electrolyte imbalances are common in patients with renal impairment, with or without diabetes, and should be addressed. Lithium: Losartan reduce lithium excretions; hence, serum lithium, and should be monitored carefully if lithium salts are to be co-administered with LOSARTAN potassium + AMLODIPINE besilate tablets. Hypotension: Excessive fall of blood pressure can occur with amlodipine in some patient, especially the elderly. In patients who are intravascularly volume-depleted, symptomatic. Pregnancy: Drugs the act as directly on the RAAS can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, LOSARTAN potassium + AMLODIPINE besilate should be discontinued as soon as possible. Oligohydramnios has also been reported, presumable resulting from decreased fatal renal function. Lactation: It is not known whether losartan or amlodipine is excreted in human milk. In the absence of this information, it is recommended that nursing may be discontinued while the combination is administered. Renal Impairment: The combination should be used with caution in patients with
ASIA PACIFIC - PHILIPPINES
2204-C West Tektite Tower, Philippine Stock Exchange Center Exchange Rd.,
Ortigas Center, Pasig City,
Verheilen Pharmaceuticals Inc. © 2015 All rights reserved.